Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Extra Pale who wrote (4586)	10/19/2000 1:46:58 PM
From: jayhawk969	Read Replies (1) \| Respond to of 10280

Thanks EP, ``Lilly has three primary programs to replace Prozac. Now one has failed,'' he said. The other two are being developed in-house, he said. ``This is a bigger blow for Sepracor than Lilly,'' said Corey Davis of Chase Hambrecht & Quist, who added that Lilly has four other drugs than Prozac that are doing exceptionally and will continue to expand company revenues. That explains a lot. One of Lilly's other options may well be looking better than the Sepracor ICE, and it may be easier to combat a generic with a product that is not just the "improved variety".